BR112015030095A2 - moduladores do receptor de cxcr7 - Google Patents

moduladores do receptor de cxcr7

Info

Publication number
BR112015030095A2
BR112015030095A2 BR112015030095A BR112015030095A BR112015030095A2 BR 112015030095 A2 BR112015030095 A2 BR 112015030095A2 BR 112015030095 A BR112015030095 A BR 112015030095A BR 112015030095 A BR112015030095 A BR 112015030095A BR 112015030095 A2 BR112015030095 A2 BR 112015030095A2
Authority
BR
Brazil
Prior art keywords
receptor modulators
cxcr7
formula
cxcr7 receptor
pharmaceuticals
Prior art date
Application number
BR112015030095A
Other languages
English (en)
Other versions
BR112015030095B1 (pt
Inventor
Heinz Fretz
Guerry Philippe
Kimmerlin Thierry
Lehembre Francois
Pothier Julien
Siendt Hervé
Valdenaire Anja
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR112015030095A2 publication Critical patent/BR112015030095A2/pt
Publication of BR112015030095B1 publication Critical patent/BR112015030095B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

MODULADORES DO RECEPTOR DE CXCR7 Refere-se a presente invenção aos derivados da fórmula (I) Fórmula (I) em que (R1) n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y e Ar1 são tais como se encontram descritos na descrição, à sua preparação, aos seus sais farmaceuticamente aceitáveis, e ao seu uso como produtos farmacêuticos, às composições farmacêuticas que contêm um ou mais compostos da fórmula (I) , e especialmente ao seu uso como moduladores do receptor de CXCR7.
BR112015030095-2A 2013-05-30 2014-05-28 Moduladores do receptor de cxcr7 BR112015030095B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2013/054478 2013-05-30
IB2013054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
BR112015030095A2 true BR112015030095A2 (pt) 2022-07-12
BR112015030095B1 BR112015030095B1 (pt) 2023-02-28

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030095-2A BR112015030095B1 (pt) 2013-05-30 2014-05-28 Moduladores do receptor de cxcr7

Country Status (31)

Country Link
US (1) US9920010B2 (pt)
EP (1) EP3004082B1 (pt)
JP (1) JP6393749B2 (pt)
KR (1) KR102302580B1 (pt)
CN (1) CN105263924B (pt)
AR (1) AR096490A1 (pt)
AU (1) AU2014272718B2 (pt)
BR (1) BR112015030095B1 (pt)
CA (1) CA2912133C (pt)
CL (1) CL2015003470A1 (pt)
CY (1) CY1119537T1 (pt)
DK (1) DK3004082T3 (pt)
EA (1) EA028604B1 (pt)
ES (1) ES2645470T3 (pt)
HK (1) HK1223353A1 (pt)
HR (1) HRP20171597T1 (pt)
HU (1) HUE036649T2 (pt)
IL (1) IL242782B (pt)
LT (1) LT3004082T (pt)
MA (1) MA38679B1 (pt)
MX (1) MX364104B (pt)
MY (1) MY173564A (pt)
NO (1) NO3004082T3 (pt)
PH (1) PH12015502632B1 (pt)
PL (1) PL3004082T3 (pt)
PT (1) PT3004082T (pt)
SG (1) SG11201509057UA (pt)
SI (1) SI3004082T1 (pt)
TW (1) TWI640510B (pt)
UA (1) UA118562C2 (pt)
WO (1) WO2014191929A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
EP3227263B1 (en) 2014-12-01 2019-04-10 Idorsia Pharmaceuticals Ltd Cxcr7 receptor modulators
WO2017070431A1 (en) * 2015-10-23 2017-04-27 James Merritt Use of ccr1 antagonists as a treatment for tumors of the central nervous system
SG11201900633XA (en) * 2016-07-28 2019-02-27 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
SI3625228T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Derivati pirimidina kot modulatorji receptorja PGE2
PT3625222T (pt) 2017-05-18 2021-10-07 Idorsia Pharmaceuticals Ltd Derivados de fenilo como moduladores do recetor de pge2
US11339148B2 (en) 2018-01-26 2022-05-24 Idorsia Pharmaceuticals Ltd. Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
TR200002427T2 (tr) 1998-02-18 2001-01-22 Neurosearch A/S Yeni bileşikler ve bunların pozitif ampa reseptör modülatörleri olarak kullanımı.
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
DE60327106D1 (de) * 2002-12-20 2009-05-20 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
AU2006315514B2 (en) * 2005-11-10 2012-03-01 Chemocentryx, Inc. Substituted quinolones and methods of use
WO2009076404A1 (en) 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
EP3227263B1 (en) 2014-12-01 2019-04-10 Idorsia Pharmaceuticals Ltd Cxcr7 receptor modulators

Also Published As

Publication number Publication date
CY1119537T1 (el) 2018-03-07
IL242782A0 (en) 2016-02-01
AU2014272718B2 (en) 2018-06-28
KR20160013197A (ko) 2016-02-03
PH12015502632A1 (en) 2016-03-07
AR096490A1 (es) 2016-01-13
TW201529557A (zh) 2015-08-01
LT3004082T (lt) 2017-10-25
MA38679A1 (fr) 2018-07-31
PL3004082T3 (pl) 2018-01-31
MX2015016429A (es) 2016-03-01
IL242782B (en) 2019-06-30
MY173564A (en) 2020-02-04
HK1223353A1 (zh) 2017-07-28
EA201501163A1 (ru) 2016-06-30
KR102302580B1 (ko) 2021-09-15
UA118562C2 (uk) 2019-02-11
NO3004082T3 (pt) 2017-12-30
PT3004082T (pt) 2017-11-13
WO2014191929A1 (en) 2014-12-04
SI3004082T1 (sl) 2017-11-30
DK3004082T3 (en) 2017-10-02
AU2014272718A1 (en) 2016-01-21
ES2645470T3 (es) 2017-12-05
CL2015003470A1 (es) 2016-06-17
NZ715530A (en) 2020-12-18
BR112015030095B1 (pt) 2023-02-28
US9920010B2 (en) 2018-03-20
TWI640510B (zh) 2018-11-11
MX364104B (es) 2019-04-12
JP6393749B2 (ja) 2018-09-19
HUE036649T2 (hu) 2018-07-30
JP2016520120A (ja) 2016-07-11
CA2912133A1 (en) 2014-12-04
CN105263924B (zh) 2018-10-19
US20160107997A1 (en) 2016-04-21
SG11201509057UA (en) 2015-12-30
CA2912133C (en) 2021-06-22
HRP20171597T1 (hr) 2017-12-01
MA38679B1 (fr) 2019-12-31
PH12015502632B1 (en) 2016-03-07
EA028604B1 (ru) 2017-12-29
EP3004082B1 (en) 2017-08-02
EP3004082A1 (en) 2016-04-13
CN105263924A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112015030095A2 (pt) moduladores do receptor de cxcr7
BR112014030173A8 (pt) Composto derivado de benzimidazol-prolina, e, composição farmacêutica
BR112019001551A2 (pt) moduladores do receptor de piperidina cxcr7
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112015007516A2 (pt) antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
BR112014010617A2 (pt) derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
BR112015000615A8 (pt) Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
BR112017016311A2 (pt) derivados de 9h-pirrolo-dipiridina
DOP2014000163A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112018010291A2 (pt) derivados de indol n-substituídos como moduladores do receptor pge2
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112017015093A2 (pt) derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3
BR112014017735A8 (pt) Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
BR112014022214A2 (pt) fenólicos antibacterianos
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
BR112015013463A8 (pt) Derivados de carboxamida indol como antagonistas do receptor de p2x7
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112016022046A2 (pt) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
BR112014031755A8 (pt) Derivados de 1-[m-carboxamido (hetero) aril-metil]-heterociclil-carboxamida
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112017015116A2 (pt) derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3
BR112016008799A8 (pt) derivados de pirazolopirimidona ou pirrolotriazona, seus usos, seus processos para sua preparação e seus intermediários, e composição farmacêutica
BR112016001238A8 (pt) Derivados de 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona, seus usos e composição farmacêutica os compreendendo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LIMITED (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LIMITED (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2014, OBSERVADAS AS CONDICOES LEGAIS